Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
- 1 October 2010
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 37 (5), 485-498
- https://doi.org/10.1053/j.seminoncol.2010.09.003
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyThe Lancet Oncology, 2010
- Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patientMelanoma Research, 2009
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with InfliximabDigestive Diseases and Sciences, 2008
- Melanoma-induced brain metastasesExpert Review of Anticancer Therapy, 2008
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- THE B7 FAMILY REVISITEDAnnual Review of Immunology, 2005
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProceedings of the National Academy of Sciences, 2003